Sialix is developing products based on new biological discoveries of non-human sialic acids, their dietary role and inflammatory consequences, and their potential impact on cancer, cardiovascular, and other inflammatory-mediated diseases. Sialix is actively pursuing the parallel development of two complementary product development programs: (1) oncology therapeutics targeting glycan alterations in solid tumors, such as ovarian, breast, and colon cancer, (2) an anti-inflammatory nutritional program to reduce chronic inflammation associated with ingestion of a non-human sialic acid which is found in red meat. Chronic inflammation has been linked to the development and progression of cancer, heart attacks, strokes, obesity, and diabetes, as well as other chronic inflammatory conditions.
Sialix’s scientific foundation was developed in the laboratory of Ajit Varki (UCSD), a world-leader in glycobiology. Sialix has licensed a broad patent portfolio of intellectual property from UCSD and assembled a team of industry veterans and glycobiology experts to support the development of these products.